59546 Alternative Splice Variant-Targeted Dendritic Cell Therapy Generates a Systemic Oligoclonal Anti-Tumor Cytotoxic T Cell Response in Diffuse Hemispheric Glioma, H3 G34-Mutant: Early Findings From a First-In-Human Clinical Trial

View at publisher Summarise with VIRAT
Authors: Anthony C. Wang, Geoffrey C. Owens, Linda M. Liau, Robert Michael Prins, Yi Xing
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

INTRODUCTION: Malignant brain tumors are the leading cause of cancer death in children. Of these, pediatric high-grade gliomas (pHGGs) present a vast challenge, with few viable treatment options and no long-term survival prospects. Recurrence is universal, as tumors invade and infiltrate the surrounding brain, making complete surgical excision impossible, while quiescent tumor-initiating cell populations evade adjuvant therapies. Adaptive anti-tumor immunity may offer a means to suppress recurrence, but has been stifled for pHGG in part due to lack of ideal antigens that are both uniformly expressed on tumor and safe to target. The two main pHGG subtypes are distinguished by somatic H3-3A gene mutations, and dysregulated mRNA processing appears to be a characteristic feature of diffuse hemispheric glioma, H3 G34-mutant (DHG). Dysregulated mRNA processing, such as alternative mRNA splicing, in cancer creates an extensive, unexplored repertoire of tumor-associated mRNA isoforms, and can serve as dominant cytotoxic T cell targets. METHODS: We developed a novel syngeneic genetically engineered mouse model using the RCAS/tv-A system to target the expression of H3/G34R and PDGFb, and to knock out p53 in neural progenitors in transgenic C57BL/6 neonatal mice. We utilized IRIS, our novel bioinformatics pipeline, to identify TAAs, and found that DCs pulsed with these TAAs provided a significant survival benefit. Based on the results of our pre-clinical murine experiments, we then opened a pilot Phase I clinical trial (NCT06342908) to investigate the safety and immunogenicity of DC therapy targeting products of mRNA dysregulation in DHG. RESULTS: One participant, after receiving IRIS-target DC therapy, showed the following tumor progression/pseudoprogression, and underwent re-resection. Analysis of post-treatment tumor tissue showed significant intratumoral T cell infiltration, with a heavy predominance of CD8+ T cells. Bulk T cell receptor (TCR) sequencing of T cells from tumor and peripheral blood demonstrated that DC treatment stimulated a notable increase in the proportion of the systemic T cell repertoire represented by TCR clones also found within tumor tissue. CONCLUSIONS: Full transcript RNAseq data allows more accurate identification of alternatively spliced mRNA, a fundamentally dysregulated process in DHG. Here, we present notable preliminary findings from a first-in-human trial of DC therapy targeting products of mRNA dysregulation, identified by IRIS analysis of tumor RNAseq in pHGG. Products of dysregulated mRNA processing in DHG can be targeted through DC therapy to engender a systemic anti-tumor cytotoxic T cell response.

Fields of Study & Subjects

Immunotherapy and Immune Responses Glioma Diagnosis and Treatment Cancer Immunotherapy and Biomarkers

Publication details

Journal / source
Neurosurgery
Volume
72
Issue
Supplement_1
Pages
305–306
Publication date
26 March 2026
Language
EN